TABLE 2.
Discontinuation and switching rates
| Treatment class | Total number of patients, n (%) | Discontinuation rate, n (%) | Switching rate a , n (%) | Most common second‐line treatment |
|---|---|---|---|---|
| Total | 1730 (100) | 1102 (63.7) | 109 (9.9) | |
| TNF inhibitor | 25 (1.4) | 18 (72.0) | 4 (22.2) | Other oral systemic therapy |
| IL‐12/23 inhibitor | 24 (1.4) | 3 (12.5) | 0 (0.0) | |
| IL‐17 inhibitor | 60 (3.5) | 30 (50.0) | 6 (20.0) | Another IL‐17 inhibitor |
| IL‐23 inhibitor | 28 (1.6) | 4 (14.3) | 1 (25.0) | IL‐17 inhibitor |
| PDE‐4 inhibitor | 953 (55.1) | 532 (55.8) | 43 (8.1) | Biologics (60%); other oral treatments b (40%) |
| Immunosuppressant | 377 (21.8) | 307 (81.4) | 20 (6.5) | Apremilast |
| Vitamin A | 263 (15.2) | 208 (79.1) | 35 (16.8) | Apremilast |
Note: TNF inhibitor includes adalimumab. IL‐12/23 inhibitor includes ustekinumab. IL‐23 inhibitor includes guselkumab. IL‐17 inhibitors include secukinumab and brodalumab. PDE‐4 inhibitor includes apremilast. Immunosuppressant includes cyclosporin. Vitamin A includes etretinate.
Abbreviations: IL, interleukin; n, number of patients; PDE‐4, phosphodiesterase‐4; TNF, tumor necrosis factor.
a
Switching rate is computed only among patients who discontinued the index treatment.
b
Includes cyclosporin and etretinate.